GP Prescribing Behaviour Change Calcium Supplement Prescribing Cessation Kenneth Chin.

Slides:

Advertisements

Similar presentations

 Osteoporosis DES › Females age who have had fragility # in last 12 months  Have they had a DEXA?  Are they on treatment with a bone sparing.

Advertisements

Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular Medicine American University of Beirut-

Produced by The Alfred Workforce Development Team on behalf of DHS Public Health - Diabetes Prevention and Management Initiative June 2005 Diabetes Prevention.

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Mortality benefit from reduction in sodium consumption 1 Hypertension affects one-third of the US population, of which less than half have their blood.

Primary care of hypertensive patients and the risk of acute events Irina Stirbu-Wagner Markus MJ Nielen Maaike Langelaan Robert A. Verheij Joke C. Korevaar.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Calcium/Vitamin D-related CV Events Based on Poster 1163 “Risk of Cardiovascular Events with Calcium/Vitamin D – a Re-Analysis of the Women’s Health Initiative”

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.

ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,

IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE

Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

NOR-MAN RHA Falls Prevention and Management Program February 2012.

A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.

The Impact of Pharmacy Safety Alerts on Thiazolidinedione Use Lee YY 1, Chiang YC 1, Kuo LN 1, Chen HY 1,2 Department of Pharmacy, Taipei Medical University.

Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,

Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment.

Methodological Issues in Systematic Review - Formulating Questions - Joseph Lau, MD Tufts Medical Center EPC AHRQ Annual Meeting September 10, 2008.

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Fat or Low-fat? Anwar T. Merchant ScD, MPH, DMD Department of Epidemiology and Biostatistics.

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.

Discontinuation of medication after nonfatal event: MI

Reducing Death and Disability Sheila Glenn

Landon Marshall, Pharm. D. , Matt Hill, Pharm. D. , Jim Wilson, Pharm

Primary Prevention of Cardiovascular Disease (CVD) Events with Statins

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Dr Mohamed Ouda MRCGP 1-Reason for choice of audit 3-Standards set

LEADER trial: Primary Outcome

First time a CETP inhibitor shows reduction of serious CV events

OSTEOPOROSIS. OSTEOPOROSIS Osteoporosis Osteoporosis affects both men and women. Its prevalence increases with age, and it is particularly common in.

on behalf of the LEADER Trial Steering Committee and Investigators

Cardiovascular disease

Cardiovascular disease

Zuzana Motovska et al. JACC 2018;71:

Diabetes Journal Club March 17, 2011

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

David J.A. Jenkins et al. JACC 2018;71:

Healthy With HIV.

Potential mechanisms whereby statins may reduce the risk of stroke

Figure 1: Assessment of basal 10-year risk of fracture with the 2010 tool of the Canadian Association of Radiologists and Osteoporosis Canada. Figure 1:

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

MATRIX: Radial vs. Femoral

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Left Ventricular Mass at MRI and Long-Term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA) Left ventricular hypertrophy.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

GP Prescribing Behaviour Change Calcium Supplement Prescribing Cessation Kenneth Chin

Background Audit. Audit. Calcium supplement discontinuation in light of recent research findings. Calcium supplement discontinuation in light of recent research findings. Bolland et al August 2010, in BMJ. Bolland et al August 2010, in BMJ. Effect of calcium supplements on risk of myocardial infarctions and cardiovascular events: meta-analysis. Effect of calcium supplements on risk of myocardial infarctions and cardiovascular events: meta-analysis.

Background Ca supplements >500mg/d had Hazard Ratio 1.27 times (30% increased risk) of MI compared to those not on calcium. Ca supplements >500mg/d had Hazard Ratio 1.27 times (30% increased risk) of MI compared to those not on calcium. More so in the elderly female population. More so in the elderly female population. “Treatment of 1000 people with calcium for 5 years would cause an additional 14 MIs, 10 Strokes and 13 deaths, while preventing 26 fractures”. “Treatment of 1000 people with calcium for 5 years would cause an additional 14 MIs, 10 Strokes and 13 deaths, while preventing 26 fractures”.

Method Audit of GP practice database using Medtech Query Builder. Audit of GP practice database using Medtech Query Builder. Female patients ≥65y. Female patients ≥65y. Prescribed Calcium Carbonate Supplements for osteoporosis management / prevention. Prescribed Calcium Carbonate Supplements for osteoporosis management / prevention. Prescribing dates for inclusion were 1 June 2010 to 31 December Prescribing dates for inclusion were 1 June 2010 to 31 December 2010.

Method All subjects’ notes were reviewed until June 2011 to determine if calcium supplements were discontinued. All subjects’ notes were reviewed until June 2011 to determine if calcium supplements were discontinued.

Results 118 audit subjects 118 audit subjects 84 (71%) - Calcium supplements discontinued between August 2010 and June (71%) - Calcium supplements discontinued between August 2010 and June 2011.

Results Of 34 (29%) still on calcium supplements: Of 34 (29%) still on calcium supplements:  13/34 T score <-2.5 ie osteoporotic.  10/34 T score > -2.5 ie osteopenic.  11/34 had no bone densitometry recorded.  Most were down to 1 tab Ca od.

Discussion 71% reduction in patients prescribed calcium supplements. 71% reduction in patients prescribed calcium supplements. The published research findings (Bolland et al) has impacted on calcium supplement prescribing behaviour in the practice. The published research findings (Bolland et al) has impacted on calcium supplement prescribing behaviour in the practice. New research findings can and do impact quickly on the management of patients in the GP setting. New research findings can and do impact quickly on the management of patients in the GP setting.

Discussion Some reasons patients remained on calcium supplements: Some reasons patients remained on calcium supplements:  Patient preference.  Poor dietary calcium intake. Important to identify patients at high risk of CVD, who remain on calcium supplements. Important to identify patients at high risk of CVD, who remain on calcium supplements.

Conclusion Practice doctors have responded quickly to new significant research findings, by appropriately modifying prescribing behaviour. Practice doctors have responded quickly to new significant research findings, by appropriately modifying prescribing behaviour. Key learning point: ongoing new research findings can and do impact rapidly on the management of patients in the GP setting. Key learning point: ongoing new research findings can and do impact rapidly on the management of patients in the GP setting.

Conclusion Relevant new management plans would need to be thoroughly discussed with patients to ensure successful implementation. Relevant new management plans would need to be thoroughly discussed with patients to ensure successful implementation. Ref: Bolland MJ et al. BMJ 2010;341: c3691.